Amgen Inc

XNASHealth care

Last traded price · USD

$455.40

−2.16%Market closed

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 06:28 IST · A quote does not mean the product is available to trade on your account.

Day's open: $463.38
Previous close: $465.45
Volume: 2.4M
Day's high: $467.04
Day's low: $460.15

In brief

Amgen Inc is a health care company listed on Nasdaq, valued at about $246.20B.
Its shares closed at $461.26 on 3 Nov 2026, up 55.7% over the past year.
From India you can buy AMGN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Amgen Inc (AMGN) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole AMGN share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade AMGN options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +14.5% (SPY −2.6%, XLV +9.9%). 3 months: +18.3% (SPY −2.2%, XLV +13.5%). 1 year: +55.7% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AMGN, SPY and XLV · as of 3 Nov 2026
3.0% below its 52-week high
Closed at $461.26 on 3 Nov 2026: 3.0% below the 52-week high of $475.65 (30 Oct 2026) and 52.7% above the low of $302.13 (5 Nov 2025).
Daily price bars, split-adjusted · as of 3 Nov 2026
Above its 50- and 200-day averages
The 3 Nov 2026 close of $461.26 was 9.6% above its 50-day average ($420.83) and 22.6% above its 200-day average ($376.12). It has closed above the 200-day for 107 sessions, since 3 Jun 2026. The 50-day average crossed above the 200-day on 13 Nov 2025, 243 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
Next ex-dividend date: 20 Nov 2026
$2.52 a share, payable 11 Dec 2026; unchanged from the previous payment (ex-date 21 Aug 2026).
Corporate actions record · as of 4 Nov 2026
Short interest at 2.5% of shares outstanding
13.4M shares were sold short at the 15 Oct 2026 settlement, 2.5% of the 540.6M shares outstanding; covering them would take 5.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month+14.5%

6 months+39.9%

1 year+55.7%

5 years+111.5%

Newswire

About

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Website

Notable moves

September 8, 2026
−10.08%
February 4, 2026
+8.15%
May 3, 2024
+11.82%

Newswire

About

Website

Notable moves

September 8, 2026
−10.08%
February 4, 2026
+8.15%
May 3, 2024
+11.82%

Amgen Inc

XNASHealth care

Last traded price · USD

$455.40

−2.16%Market closed

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 06:28 IST · A quote does not mean the product is available to trade on your account.

Day's open: $463.38
Previous close: $465.45
Volume: 2.4M
Day's high: $467.04
Day's low: $460.15

In brief

Amgen Inc is a health care company listed on Nasdaq, valued at about $246.20B.
Its shares closed at $461.26 on 3 Nov 2026, up 55.7% over the past year.
From India you can buy AMGN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Amgen Inc (AMGN) shares from India?

Do I need the price of a whole AMGN share to invest?

How much can I invest in US stocks in a year?

Can I trade AMGN options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +14.5% (SPY −2.6%, XLV +9.9%). 3 months: +18.3% (SPY −2.2%, XLV +13.5%). 1 year: +55.7% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AMGN, SPY and XLV · as of 3 Nov 2026
3.0% below its 52-week high
Closed at $461.26 on 3 Nov 2026: 3.0% below the 52-week high of $475.65 (30 Oct 2026) and 52.7% above the low of $302.13 (5 Nov 2025).
Daily price bars, split-adjusted · as of 3 Nov 2026
Above its 50- and 200-day averages
The 3 Nov 2026 close of $461.26 was 9.6% above its 50-day average ($420.83) and 22.6% above its 200-day average ($376.12). It has closed above the 200-day for 107 sessions, since 3 Jun 2026. The 50-day average crossed above the 200-day on 13 Nov 2025, 243 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
Next ex-dividend date: 20 Nov 2026
$2.52 a share, payable 11 Dec 2026; unchanged from the previous payment (ex-date 21 Aug 2026).
Corporate actions record · as of 4 Nov 2026
Short interest at 2.5% of shares outstanding
13.4M shares were sold short at the 15 Oct 2026 settlement, 2.5% of the 540.6M shares outstanding; covering them would take 5.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month+14.5%

6 months+39.9%

1 year+55.7%

5 years+111.5%

Newswire

About

Website

Notable moves

September 8, 2026
−10.08%
February 4, 2026
+8.15%
May 3, 2024
+11.82%

Newswire

About

Website

Notable moves

September 8, 2026
−10.08%
February 4, 2026
+8.15%
May 3, 2024
+11.82%

Amgen Inc

Amgen Inc in brief

Ahead of SPY and its sector fund XLV over 1 year

3.0% below its 52-week high

Above its 50- and 200-day averages

Next ex-dividend date: 20 Nov 2026

Short interest at 2.5% of shares outstanding

Amgen Inc

Amgen Inc in brief

Ahead of SPY and its sector fund XLV over 1 year

3.0% below its 52-week high

Above its 50- and 200-day averages

Next ex-dividend date: 20 Nov 2026

Short interest at 2.5% of shares outstanding